Article Text
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is one of the most innovative therapies for haematological malignancies to emerge in a generation. Clinical studies have shown that a single dose of CAR T-cells can deliver durable clinical remissions for some patients with B-cell cancers where conventional therapies have failed.
A significant complication of CAR therapy is the immune effector cell-associated neurotoxicity syndrome (ICANS). This syndrome presents a continuum from mild tremor to cerebral oedema and in a minority of cases, death. Management of ICANS is mainly supportive, with a focus on seizure prevention and attenuation of the immune system, often using corticosteroids. Parallel investigation to exclude other central nervous system pathologies (infection, disease progression) is critical. In this review, we discuss current paradigms around CAR T-cell therapy, with a focus on appropriate investigation and management of ICANS.
- Tumours
- Toxicology
- Neuropathology
- Neurooncology
- Epilepsy
- Paraneoplastic syndrome
- Clinical neurology
- Haematology
- Oncology
Statistics from Altmetric.com
Footnotes
Contributors NL, JR and CR authors contributed to the final version of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests CR has received speaker fees from Novartis, Kite Gilead and Celgene. LN has been supported by Celgene to attend an academic conference.
Patient consent for publication Not required.
Provenance and peer review Commissioned. Externally peer reviewed by David McKee, Manchester, UK.
Read the full text or download the PDF:
Other content recommended for you
- CAR-T treatment for hematological malignancies
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- Unexpected neurologic complications following a novel lymphoma treatment ‘expected’ to give rise to neurologic toxicity
- Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
- Cardiotoxicities of novel cancer immunotherapies
- What is CAR T-cell therapy?
- Novel treatments in B cell non-Hodgkin’s lymphomas
- Emerging immunotherapies in multiple myeloma
- Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment